Showing 4151-4160 of 4262 results for "".
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- European Commission Grants Conditional Approval to Erivedgehttps://practicaldermatology.com/news/20130716-european_commission_grants_conditional_approval_to_erivedge/2459497/The European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. The Commission granted the conditional approval based upon t
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- MiraConnect Lets Candidates Interact with miraDry Treatment Veteranshttps://practicaldermatology.com/news/20130625-miraconnect_lets_candidates_interact_with_miradry_treatment_veterans/2459509/Offering an opportunity for interested to learn more about microwave-based therapy for hyperhidrosis, the miraConnect program from Miramar Labs enables treatment candidates to speak one-on-one with patients who have undergone the procedu
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- Georgia Governor Signs AMA Model Legislationhttps://practicaldermatology.com/news/20130520-georgia_governor_signs_ama_model_legislation/2459538/Georgia lawmakers enacted legal protections for physicians engaged in quality and delivery improvement initiatives included in the federal health care reform law. This first-of-its-kind legislation reinforces the concept that medical decisions are made based on a patient's unique medical needs. The
- Onset Dermatologics Unveils Anti-Itch Gel for Eczemahttps://practicaldermatology.com/news/20130515-onset_unveils_anti-itch_gel_for_eczema/2459544/A new product for itching associated with eczema is now available from Onset Dermatologics. Aurstat® Anti-Itch Hydrogel is engineered to soothe itching, burning, and pain of atopic dermatitis and various dermatoses, according to the company. The patented hydrogel formulation is alcohol free, fragran
- Corena Therapeutics New to Industryhttps://practicaldermatology.com/news/20130513-corena_therapeutics_new_to_industry/2459546/The emerging Swiss dermatological products company Corena Therapeutics provides safe alternatives to popular treatments. Coresatin, its latest brand of five steroid-free creams, is safely formulated for pediatric patients, according to the
- Thermage Total Tip Available to Dermatologists Nationwidehttps://practicaldermatology.com/news/20130510-thermage_total_tip_available_to_dermatologists_nationwide/2459548/Solta Medical, Inc. launched the Thermage Total Tip 3.0 for face, neck, and body treatments. Targeted, uniform, bulk heating allows dermatologists to treat patients effectively while maintaining patient comfort, according to the company. Thermage
- Lambrolizumab Designated as Breakthrough Therapyhttps://practicaldermatology.com/news/20130429-lambrolizumab_designated_as_breakthrough_therapy/2459556/Merck & Co. received breakthrough therapy designation from the US Food and Drug Administration for its lambrolizumab drug as a treatment of patients with advanced melanoma. Lambrolizumab is Merck's investigational antibody therapy targeting Programm